---
title: "Drugmakers Climb On Q2 Reports, Even As One Misses Profit Views"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294249205.md"
description: "Positive guidance from Teva Pharmaceuticals overshadowed their second-quarter results, which were a mix of strong and weak performances. The pharmaceutical company reported earnings in the second quarter, causing a surge in their stock price despite falling short of profit expectations. The overall trend in the industry saw drugmakers experiencing growth as they released their Q2 reports. The positive movement was evident in stock prices, with Teva leading the climb with promising forecasts. This news was well received in the investment community."
datetime: "2026-07-29T19:04:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294249205.md)
  - [en](https://longbridge.com/en/news/294249205.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294249205.md)
---

# Drugmakers Climb On Q2 Reports, Even As One Misses Profit Views

Positive guidance from Teva Pharmaceuticals overshadowed their second-quarter results, which were a mix of strong and weak performances. The pharmaceutical company reported earnings in the second quarter, causing a surge in their stock price despite falling short of profit expectations. The overall trend in the industry saw drugmakers experiencing growth as they released their Q2 reports. The positive movement was evident in stock prices, with Teva leading the climb with promising forecasts. This news was well received in the investment community.

### Related Stocks

- [TEVA.US](https://longbridge.com/en/quote/TEVA.US.md)

## Related News & Research

- [Teva EVP Business Development Evan Lippman sells 18,600 shares for $680,291.28](https://longbridge.com/en/news/296394259.md)
- [Aurinia settles Teva patent suit, sets generic voclosporin launch no earlier than Dec. 7, 2036](https://longbridge.com/en/news/296394736.md)
- [FDA accepts Teva ecopipam NDA for pediatric Tourette syndrome, grants priority review](https://longbridge.com/en/news/296355997.md)
- [Is Teva Pharmaceutical Industries (TEVA) A Bargain On Its TEV 408 Phase 2b Move?](https://longbridge.com/en/news/296006711.md)
- [Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Reports Lower Q2 Expenses, Advances Lucid-MS Into Phase 2](https://longbridge.com/en/news/296129489.md)